<DOC>
	<DOCNO>NCT01658176</DOCNO>
	<brief_summary>PF-04691502 inhibitor PI3K mTOR kinase . Exemestane aromatase inhibitor treatment advance breast cancer woman whose disease progress follow tamoxifen therapy . The combination PF-04691502 exemestane might mitigate resistance hormonal therapy result great clinical benefit exemestane alone woman estrogen receptor positive advance breast cancer .</brief_summary>
	<brief_title>Study Of PF-04691502 ( PI3K/mTOR Inhibitor ) In Combination With Exemestane Compared With Exemestane Alone In Patients With Advanced Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<criteria>Inoperable estrogen receptor positive , Her2 negative advance breast cancer Previously treat aromatase inhibitor Primary secondary hormone resistance Acceptable glucose control , bone marrow , liver kidney function Inflammatory breast carcinoma Prior therapy agent active PI3K , Akt , and/or mTOR Known hypersensitivity exemestane Significant gastrointestinal abnormality may impair intake , transit , absorption study drug Current anticipate need food drug know inhibitor inducer CYP3A4</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Estrogen receptor positive</keyword>
	<keyword>Her-2 negative</keyword>
	<keyword>advanced breast cancer</keyword>
	<keyword>Breast Cancer</keyword>
</DOC>